| Cash Flow | 2025-09-30 | 2025-06-30 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
| Net loss | -439,950 | -273,911 | -104,359 | -222,434 |
| Share-based compensation | 163,999 | 82,178 | 205,541 | 121,860 |
| Change in fair value of investments | 109,376 | -19,125 | 42,287 | 63,601 |
| Change in fair value of debt and liability instruments | -23,288 | -2,329 | 98,954 | 102,137 |
| Gain on sale of subsidiary interests | - | - | 376,506 | - |
| Gain on deconsolidation of subsidiaries | - | - | 0 | 0 |
| Gain on sale of telavant net assets | 0 | 0 | 110,387 | 110,387 |
| Accretion of discount and amortization of premium on marketable securities, net | 20,883 | 11,061 | 54,304 | 25,036 |
| Loss on extinguishment of debt | - | - | -8,848 | - |
| Depreciation and amortization | 2,019 | 1,098 | 12,646 | 9,725 |
| Non-cash lease expense | 3,885 | 1,943 | 4,871 | 3,160 |
| Other | -17,062 | -11,082 | 465 | 12,360 |
| Other current assets | 4,262 | -128 | 53,922 | 12,206 |
| Accounts payable | -8,749 | -11,745 | -18,003 | -18,057 |
| Accrued expenses | -12,480 | -25,000 | -19,507 | -16,474 |
| Operating lease liabilities | -1,324 | -478 | -5,459 | -3,444 |
| Other | 3,276 | 71 | 14,639 | 8,244 |
| Net cash used in operating activities | -390,047 | -204,383 | -666,886 | -459,635 |
| Purchases of marketable securities | 2,778,411 | 1,801,681 | 4,061,521 | 3,402,985 |
| Maturities of marketable securities | 1,825,000 | 720,000 | 960,000 | - |
| Purchase of property and equipment | 11,883 | 4,035 | 3,788 | 1,961 |
| Proceeds from sale of subsidiary interests | 0 | - | 185,586 | 110,387 |
| Proceeds from sale of telavant net assets, net | - | - | 110,387 | - |
| Cash decrease upon deconsolidation of subsidiaries | - | - | 31,149 | 0 |
| Other | - | - | 0 | 0 |
| Net cash used in investing activities | -965,294 | -1,085,716 | -2,840,485 | -3,294,559 |
| Proceeds from issuance of the company's common shares, net of issuance costs paid | - | - | 0 | 0 |
| Proceeds from issuance of subsidiary common shares, net of issuance costs paid | - | - | 0 | - |
| Payment of subsidiary dividend | - | - | 0 | 0 |
| Repayment of debt by subsidiary | 0 | 0 | 51,979 | 3,000 |
| Payments on principal portion of finance lease obligations | 0 | 0 | 774 | 662 |
| Proceeds from exercise of the companys and subsidiary stock options | 98,351 | 30,057 | 37,006 | 8,891 |
| Taxes paid related to net settlement of equity awards | 16,013 | 9,532 | 29,755 | 21,128 |
| Repurchase of common shares | 208,293 | 208,293 | 997,787 | 754,439 |
| Proceeds from issuance of the companys common shares under employee stock purchase plan | 774 | - | 648 | 648 |
| Proceeds from exercise of the company's warrants | - | - | 0 | 0 |
| Payment for redemptions of the company's warrants | - | - | 0 | 0 |
| Net cash used in financing activities | -125,181 | -187,768 | -1,042,641 | -769,690 |
| Effect of exchange rate changes on cash, cash equivalents, and restricted cash | 2,021 | 815 | 1,236 | 2,303 |
| Net change in cash, cash equivalents and restricted cash | -1,478,501 | -1,477,052 | -4,548,776 | -4,521,581 |
| Cash and cash equivalents at beginning of period | 2,725,661 | 2,725,661 | 6,550,450 | 6,550,450 |
| Cash and cash equivalents at end of period | 1,247,160 | 1,248,609 | 2,001,674 | 2,028,869 |
Roivant Sciences Ltd. (ROIV)
Roivant Sciences Ltd. (ROIV)